Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 05, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,502.94 pence per share.
- Total Treasury Shares Held: 177,301,678 shares following the transaction.
- Shares in Issue: 5,806,486,878 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 500,000 shares for Treasury. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (500,000 shares at 1,502.94 pence) against the company's cash position in broader financial reports.
- Confirm the updated share count of 5,806,486,878 shares in issue for earnings per share calculations.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authority utilized.